These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35389589)

  • 1. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
    Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
    J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
    J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
    Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    Patient Prefer Adherence; 2020; 14():517-527. PubMed ID: 32210539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
    J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
    Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
    J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
    Blauvelt A; Shi N; Burge R; Atiya B; Zhu B; Somani N; Ridenour T; Lew CR; Zimmerman NM; Murage MJ
    Pharmacoecon Open; 2022 Nov; 6(6):871-880. PubMed ID: 36155891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
    Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.
    Srulovici E; Garg V; Ghilai A; Feldman B; Hoshen M; Balicer RD; Skup M; Leventer-Roberts M
    Adv Ther; 2018 May; 35(5):655-665. PubMed ID: 29748914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
    Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
    Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, persistence and treatment switching in psoriasis.
    Santoleri F; Musicco F; Fulgenzio C; Abrate P; Pestrin L; Pasut E; Modesti G; Giannini R; Rosa S; Piccoli M; Mingolla G; Zuzolo E; Gazzola P; Roperti M; Pieri G; Montresor V; Martignoni I; Gambera M; Langella R; Tinari G; Spoltore C; Roberti C; Fabio LD; Grossi L; Guarino F; Vita F; Lasala R; Costantini A
    Immunotherapy; 2024; 16(9):611-621. PubMed ID: 38651935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.